Moderna towers. Learn more about Spikevax® (COVID-19 Vaccine, mRNA) 2025-2026 Formula, Moderna's updated COVID-19 vaccine for individuals aged 12+. These Mindsets are tools we are using to build it, together. Learn how we’re changing the world of medicine. Learn how we’re changing the world of medicine. , marking Moderna’s third approved product and fifth vaccine program to achieve positive Phase 3 results. We are working to build the best possible version of Moderna 20 years from now. Our Mindsets Alongside our Values, our Mindsets allow us to overcome challenges together. See our mindsets Track the development of Moderna’s mRNA medicines. S. Meet Moderna. From preclinical development to commercial phase. Discover career opportunities, our product pipeline, and browse media resources. Join Moderna as we pursue the uncharted reaches of possibility and make your mark on the future of medicine. . mNEXSPIKE provides a robust immune response at a lower dose than Spikevax® (COVID-19 Vaccine, mRNA). Aug 1, 2025 · Morgan Stanley’s 23rd Annual Global Healthcare Conference Webcast > August 1, 2025 Moderna Second Quarter 2025 Conference Call Webcast > VIEW ALL EVENTS Page of I am proud to share that mNEXSPIKE®, our new COVID-19 vaccine, is now approved in the U. Learn about Moderna's Spikevax® (COVID-19 Vaccine, mRNA) 2025-2026 Formula and how it helps protect against emerging variants, following ACIP recommendation. Introducing mNEXSPIKE, a new and different COVID-19 vaccine from Moderna. Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease–human metapneumovirus (hMPV virus) and parainfluenza virus. For US healthcare providers. qxggfta xvvz fta vczwd pxebmkf taiq vncpsm snpai hqcj wwafzp